

Allegato B

Decreto Rettore Università di Roma “La Sapienza” n 2307/2018 del 19.09.2018

MARIANNA MARANGHI

Curriculum Vitae

Place: Roma

Date: 17/10/2018

Part I – General Information

Full Name	Marianna Maranghi
Spoken Languages	Italian, English

Part II – Education and Fellowships

IIA – Education

Type	Dates	Institution	Notes
University graduation	1994 - 2000	University of Rome Sapienza	Degree in Medicine and Surgery
Post-graduate studies	2000 - 2005	University of Rome Sapienza	Board in Internal Medicine
PhD	2005 - 2009	University of Rome Sapienza	Degree in Biomedical Technologies in Clinical Medicine
NLA Master in Lipidology Advanced Training and Board Review Course	2008	National Lipid Association (USA)	Master in Lipidology
Master Degree in	2012	University of Rome	Master Degree in Diabetology

Diabetology		Sapienza	
-------------	--	----------	--

IIA – Fellowships

Type	Dates	Institution	Responsible
Clinical-Research Fellowship	01/02/2001-01/04/2001	Laboratory of the Department of Clinical Pharmacology – Trinity College Dublin	D. Fitzgerald, MD
	01/08/2006-31/08/2006	Center for Human Nutrition – The University of Texas, Southwestern Medical Center (Dallas, USA)	N. Abate. MD
	07/01/2009 - 28/02/2010	Research Program Unit Biomedicum Haartmaninkatu 8, 00029 Helsinki Helsinki University Finland	Marja-Riitta Taskinen, MD
	01/03/2010-30/11/2011	Department of Internal Medicine and Medical Specialties Viale del Policlinico 155 Sapienza University of Rome	Sebastiano Filetti, MD

Part III – Appointments

IIIA – Academic Appointments

Start	End	Institution	Position
-------	-----	-------------	----------

01/12/2011	Present	University of Rome Sapienza, Department of Internal Medicine and Medical Specialties	Assistant Professor of Internal Medicine
01/09/2016	Present	University of Rome Sapienza,	Responsible of the Examination for the Degree Programme “Physiotherapy” Course C; (code:1034838 degree: bachelors), San Giovanni Addolorata Rome, Medicine and Dentistry Faculty
01/09/2017	Present	University of Rome Sapienza,	Coordinator of the Integrated Course Rehabilitation in Geriatric Area (code: 16013) for the Degree Programme “Physiotherapy” Course C (code: 1034838), Medicine and Dentistry Faculty, San Giovanni Addolorata Rome, Medicine and Dentistry Faculty
23/07/2018	Present	University of Rome Sapienza	Teacher of the Teaching Quality and Innovation Working Group (GDL-QuID), University of Rome Sapienza
25/01/2016	Present	University of Rome Sapienza	Member of the Medical Education Committee Inter Faculty (CMEI)
03/04/2018	03/04/2024	Italian Ministry of Education, Universities and Research (MIUR)	Awarded the National Scientific Qualification for Associate Professor for the SC 06/B1, SSD MED/09, Call 2017 (D.D. 1532/2016)

IIIB – Clinical Appointments

Start	End	Institution	Position
1/02/2007	31/12/ 2009	Policlinico Umberto I , Unit of Internal Medicine	Medical director, grade 1

		and Metabolic Diseases	
17/04/2013	Present	Policlinico Umberto I of Rome, Unit of Internal Medicine and Metabolic Diseases	Medical Doctor in Internal Medicine
16/06/2017	Present	Policlinico Umberto I of Rome, Unit of Internal Medicine and Metabolic Diseases	Responsible (IP) of the Management of Dyslipidemia and Cardiovascular Disease in Type 2 Diabetes , Unit of Internal Medicine and Metabolic Diseases

IIIC – Other Appointments: Institutional Committee Activities

Start	End	Institution	Activity
30/09/2013	Present	Italian Society of the study of Atherosclerosis (SISA) - Lazio	Member of the SISA Board (Lazio section)
02/02/2015	Present	Italian Society of the study of Atherosclerosis (SISA)	Member and Coordinator of the SISA Young Member Group
31/03/2016	Present	Italian Society of the study of Atherosclerosis (SISA)	Member of the Italian Network for the study of Genetic Dyslipidemias “LIPIGEN”

Part IV – Teaching experience

IV A- Supervisor of *Single Cycle, Bachelor Degree in Medicine and Surgery*

Dates	Student Freshman and Thesis Title	Degree/Programme/Course
2013-2014	N.1236174” Relazione tra obesità e tumore differenziato della tiroide: studio caso-controllo”	University of Rome Sapienza, Medicine and Surgery
2014-2015	N. 1338458 “ Ruolo della variante rs738409 del gene PNPLA3 su parametri metabolici e antropometrici in un campione di popolazione italiana sana”	University of Rome Sapienza, Medicine and Surgery

2014-2015	N. 1243473 “ Relazione tra HDL colesterolo e danno vascolare in soggetti con diabete mellito tipo 2”	University of Rome Sapienza, Medicine and Surgery
2015-2016	N. 1402235 “Effetti del monitoraggio della glicemia (CGM) come strumento educativo per migliorare il compenso metabolico in soggetti con diabete tipo2 sovrappeso ed in terapia insulinica basal bolus”	University of Rome Sapienza, Medicine and Surgery
2015-2016	N. 1408426 “Variabilità glicemica settimanale e nel weekend in pazienti affetti da diabete mellito tipo 2 in terapia insulinica multi-iniettiva e scompenso glicometabolico: uno studio pilota. “	University of Rome Sapienza, Medicine and Surgery
2016-2017	N. 1462138 “La terapia con DPP-IV inibitori e GLP-1 analoghi: prescrizione, efficacia e prosecuzione della terapia in soggetti con diabete mellito tipo 2 “	University of Rome Sapienza, Medicine and Surgery
2016-2017	N. 1143376 “ Studio delle caratteristiche fenotipiche di pazienti con diagnosi clinica di Ipercolesterolemia Familiare in presenza o assenza di mutazione genetica”	University of Rome Sapienza, Medicine and Surgery
2017-2018	N. 1448170 “ Analisi dati del sistema Freestyle Libre: studio pilota di valutazione bisettimanale del monitoraggio e di efficacia sul controllo glicemico”	University of Rome Sapienza, Medicine and Surgery

IVB - Supervisor of *Internal Medicine Resident Thesis*

Dates

Student Freshman and Thesis Title

Course

2013-2014	N. 941037 “Effetti del trattamento	Internal Medicine (code: 28270); University of
-----------	------------------------------------	--

	con insulina Degludec e Glargine sulla variabilità glicemica in una popolazione di pazienti diabetici di tipo 2 insulin-naive"	Rome Sapienza, Medicine and Surgery
2014-2015	N. 1048032 "Aterosclerosi coronarica precoce e Cholesterol Burden nei giovani adulti affetti da ipercolesterolemia familiare eterozigote"	Internal Medicine (code: 28270); University of Rome Sapienza, Medicine and Surgery
2015-2016	N. 1103615 " Analisi della variabilità glicemica in soggetti lavoratori e pensionati affetti da diabete mellito tipo 2: studio pilota."	Internal Medicine (code: 28270); University of Rome Sapienza, Medicine and Surgery

IVC – Teacher in Single Cycle, Bachelors Degree

Dates	Institution/Faculty	Degree/Programme/Course
01/02/2013 - present	University of Rome Sapienza, Medicine and Dentistry	Bachelors/ "Physiotherapy" Course C (code: 16013) San Giovanni Addolorata Rome, Medicine and Dentistry Faculty ; Internal Medicine
01/11/2013 - 31/10/2016	University of Rome Sapienza/Pharmacy and Medicine	Single Cycle/Medicine and Surgery A (code: 26647)/Clinical scientific methods VI
01/11/2016 - present	University of Rome Sapienza/Pharmacy and Medicine	Single Cycle/Medicine and Surgery F (code: 15342)/ Internal Medicine and General Surgery III
01/09/2018 - present	University of Rome Sapienza/Pharmacy and Medicine	Single Cycle/Medicine and Surgery F (code:15342)/ Applied Medical Scientific Methods VII

IVD – Specialization course

Dates	Institution/Faculty	Programme
-------	---------------------	-----------

01/11/2013 - present	University of Rome Sapienza/Pharmacy and Medicine	Internal Medicine (code: 28270)
01/11/2013-31/10/2015	University of Rome Sapienza/Pharmacy and Medicine	Clinical Pathology and Clinical Biochemistry (code: 29358)

IVE – PhD Degree

Dates	Institution	Programme
01/11/2013 –31/11/2017	University of Rome Sapienza	Biotechnology in Clinical Medicine (code: 11124)
01/12/2017-present	University of Rome Sapienza	Data Science (code: 30101)

IVF – Master Degree

Dates	Institution	Programme/Course
01/02/2014 - present	University of Rome Sapienza	Clinical Nutrition and Metabolism (code: 15302)

Part V - Society memberships, Awards and Honors

Dates	Title
2012 - present	Member of the “Società Italiana per lo studio dell’aterosclerosi”(SISA)
2012 - present	Member of the “Società Italiana di Medicina Interna” (SIMI)
2013 - present	Member of the “Collegio dei Docenti Universitari MED/09 di Medicina Interna” (COLMED)
2013-2015	Member of the “Endocrine Society” (USA)
2006-2008	Member of the National Lipid Association (USA)
28/11/2012	Marcello Santoro Prize Fondazione SISA

Part VI - Funding Information [grants as PI-principal investigator or subinvestigator]

Dates	Title	Program	Grant value
-------	-------	---------	-------------

2012	Familial combined hypolipidemia: clinical and biochemical characterization (Principal Investigator) (codice C26A12FAAE)	2012 University of Rome Sapienza Grant 31/12/2012	37.964,00 euro
2014	Effects of oral fat load on lipids, lipoproteins, energy expenditure and macronutrient oxidation in subjects with familial combined hypobetalipoproteinemia type 2 (FHBL2) (Principal Investigator) (codice C26A14NAX8)	2014 University of Rome Sapienza Grant	10.000,00 euro
2016	Association of low-grade inflammation markers with subclinical atherosclerosis in subjects with metabolically and genetically determined ectopic liver fat accumulation (sub-investigator)(codice RM116154CA70843D)	2014 University of Rome Sapienza Grant	10.000,00 euro
2017	Effetti del monitoraggio continuo della glicemia come strumento educativo per migliorare il compenso glicometabolico in una popolazione di soggetti diabetici di tipo 2 obesi in terapia insulinica multi-iniettiva in fase di scompenso glicometabolico (Principal Investigator) (codice RP11715C7EC027A9)	2017 University of Rome Sapienza Grant	4.000,00 euro
2016-present (5 years)	ANGPTL3 deficiency and atherosclerosis in humans (NIH Grant R01HL131961-03) (sub-investigator)	National Institutes of Health (USA)	650.000,00 euro

Part VII – Research Activities

VIIA – Research Interests

Keywords	Brief Description
Cardiovascular and Metabolic Disease	– Evaluation of lipoprotein metabolism in diabetes and genetic dyslipidemias – Characterization of atherosclerotic disease and phenotypic profile of subjects with Genetic Dyslipidemias (Angptl3 deficiency, Heterozygous Familial Hypercholesterolemia) – Evaluation of the relation between liver fat and lipoproteins metabolism – New Technologies applied to type 2 diabetes mellitus management
Big data	– Creating and assembling database networks within a single country or in the context of a multinational collaboration for studying and improving patient care through clinical epidemiologic research (currently established database and collaborations: Italian Network for the study of Genetic Dyslipidemias “LIPIGEN”)
Thyroid nodule	– Defining the thyroid nodule risk of malignancy according to sonographic pattern and molecular profile
Thyroid cancer	– Defining new thyroid cancer staging systems to predict the post-operative risk of persistent/recurrent disease

VII B – Coordination or participation to National or International Research Projects

Dates	Setting	Title
03/02/2000 – 01/10/2001	International	Bioavailability of vitamin E as function of food intake in healthy subjects: effects on plasma peroxide-scavenging activity and cholesterol-oxidation products.
01/02/2003 – 01/09/2003	National	Impact of fractures on health care in a major university hospital in Rome.
15/01/2004 – 02/11/2006	National	Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules

01/01/2005- 01/05/2007	National	Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer.
12/01/2007 – 18/12/2009	National (Coordination)	The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism modulates the beneficial effect of weight loss on fasting glucose in non-diabetic individuals
10/01/2008 – 18/12/2008	National (Coordination)	Poor glycemic control is an independent risk factor for low HDL cholesterol in patients with type 2 diabetes.
31/11/2008- 30/09/2010	National	Growth factor receptors gene expression and Akt phosphorylation in benign human thyroid nodules are unaffected by chronic thyrotropin suppression.
15/01/2008 – 11/02/2011	National	Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes
10/01/2008- 01/01/2011	National	Regulation of sodium/iodide symporter and lactoperoxidase expression in four human breast cancer cell lines.
07/01/2009 – 28/02/2010	International (Coordination)	HDL function in the Finnish Field study
16/01/2009 – 05/07/2011	International (Coordination)	High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy
20/01/2009 – 20/05/2011	International (Coordination)	Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy
16/03/2009 – 30/08/2011	International (Coordination)	Dietary omega-3 polyunsaturated fatty acid intake is related to a protective high-density lipoprotein subspecies profile independent of genetic effects: a monozygotic twin pair study
30/03/2009 – 19/04/2013	International (Coordination)	Acquired liver fat is a key determinant of serum lipid alterations in healthy monozygotic twins
28/05/2010 – 08/06/2011	National	BRAF (V600E) mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas

15/03/2011 – 29/03/2013	International	Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism
16/01/2012 – 24/04/2013	International (Coordination)	Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids
10/10/2012 – 28/08/2013	International	Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis
01/01/2013- 01/02/2015	National	Atherogenic dyslipidemia in children: evaluation of clinical, biochemical and genetic aspects.
15/11/2012 – 10/10/2013	National	Functional and morphological vascular changes in subjects with familial combined hypolipidemia: an exploratory analysis
10/01/2015 – 14/12/2015	National	Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients
15/01/2015 – 28/04/2017	International	Early coronary calcifications are related to cholesterol burden in heterozygous familial hypercholesterolemia
01/01/2016	International	ANGPTL3 deficiency and atherosclerosis in humans (NIH Grant R01HL131961-03)
01/01/2014- 01/08/2015	National	A novel double mutation val648ile and val804leu of ret proto-oncogene in multiple endocrine neoplasia type 2.
31/03/2016- 31/12/2016	National	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN).
31/03/2016- 31/12/2016	National	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study.
01/01/2017- 01/04/2018	National	Lack of association between obesity and aggressiveness of differentiated thyroid cancer.

VIIC – Participation to International Clinical Trials

Dates	Position	Title	ClinicalTrials.gov
2008-2010	Sub-Investigator	The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus	NCT00700817
2008-2014	Sub-Investigator	A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease (ARRIVE)	NCT00501059
2008-2010	Sub-Investigator	Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes (BEGIN™)	NCT00972283
2008-2010	Sub-Investigator	Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes	NCT00860288
2009-2010	Sub-Investigator	MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)	NCT00722371
2010-2016	Sub-Investigator Principal Investigator (from 01/09/2015)	Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER®)	NCT01179048
2011-2012	Sub-Investigator	Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)	NCT01296412
2012-2013	Sub-Investigator	Study of Sitagliptin for the Treatment of Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin (MK-0431-260)	NCT01462266

2011-Present	Sub-Investigator Principal Investigator (from 01/09/2015)	VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus	NCT01528254
2012-2013	Sub-Investigator	The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification	NCT01664247
2013-2016	Sub-Investigator Principal Investigator (from 01/09/2015)	A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)	NCT01703208
2013-2015	Sub-Investigator	Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes (SUSTAIN™ 3)	NCT01885208
2013-2014	Sub-Investigator	Multiple Dose Trial Examining Dose Range, Escalation and Efficacy of Oral Semaglutide in Subjects With Type 2 Diabetes	NCT01923181
2014-2016	Sub-Investigator Principal Investigator (from 01/09/2015)	A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events (DEVOTE)	NCT01959529
2017-2018	Principal Investigator	Efficacy and Safety of Oral Semaglutide Versus Empagliflozin in Subjects With Type 2 Diabetes Mellitus (PIONEER 2)	NCT02863328

2018-ongoing	Principal Investigator	Multinational cross sectional observational study to describe glycemic control and quality of life for type 1 diabetic adult patients" (Sanofi OBS15151)	
2018-ongoing	Principal Investigator	Efficacy and Safety of Sotagliflozin Versus Placebo and Empagliflozin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control While Taking a DPP4 Inhibitor Alone or With Metformin (SOTA-EMPA)	NCT03351478
2017-2018	Principal Investigator	A Trial Investigating the Cardiovascular Safety of Oral Semaglutide in Subjects With Type 2 Diabetes (PIONEER 6)	NCT02692716
2016-2018	Principal Investigator	A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin (REGAIN CONTROL)	NCT02967211

Part VIII– Editorial and Review Activities

VIII A – Editor/Service on Editorial Board(s)

Start	End	Journal	Position
01/11/2014	Present	Nutrition, Metabolism & Cardiovascular Diseases	Member of the Editorial Board (Hyperlipidemia and Atherosclerosis)

VIII B – Journal Reviewer

Journal

Nutrition, Metabolism & Cardiovascular Diseases

Endocrine
Journal of Endocrinological Investigation

Part IX- Conferences and Symposia

Invited Speaker at National Conferences promoted by National Scientific Societies

Dates	Conference/ Site	Title
02/12/2011 – 02/12/2011	25° Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA)	Iperlipemia familiare combinata o sindrome metabolica: un dilemma
24/03/2012 – 24/03/2012	Convegno della Società Italiana per lo Studio dell'Arteriosclerosi (SISA) regionale	Indicazioni terapeutiche nella dislipidemia dei pazienti con insufficienza renale cronica
29/11/2012 – 29/11/2012	26° Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA)	A new possible role for Angiopoietin like 3, a regulator of triglyceride metabolism, in modulating insulin resistance
29/11/2012 – 29/11/2012	26° Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA)	HDL e rischio cardiovascolare
18/05/2013 – 18/05/2013	Convegno della Società Italiana per lo Studio dell'Arteriosclerosi (SISA) regionale	Iperlipidemia familiare combinata: inquadramento e terapia
27/11/2013 – 29/11/2013	27° Congresso Nazionale della Società Italiana per lo Studio dell'Arteriosclerosi (SISA)	S17X loss of function (LOF) mutation in Angiopoietin like 3 (Angptl3) is associated with increased plasma lipoprotein lipase activity and changes in lipoprotein composition
11/04/2015 – 11/04/2015	Convegno della Società Italiana di Medicina Interna (SIMI). Sezione Lazio	Diabete Gestione del follow-up: prevenzione delle complicanze cardiovascolari

03/02/2016 – 03/02/2016	ATTD 2016 9th International Conference on Advanced Technologies & Treatments for Diabetes.	Selecting and initiating suitable Type 2 patients on insulin pump therapy – Practical session
11/03/2016-12/03/2016	Ipertensione arteriosa, dislipidemie ed aterosclerosi: nuovi link fisiopatologici e terapeutici SPRING meeting SISA-SIIA	Angiopoietin-like protein 3 and familial combined hypolipidemia
21/10/2016 – 21/10/2016	Convegno della Società Italiana per lo Studio dell'Arteriosclerosi (SISA) regionale. Sezione Lazio: L'evoluzione nella prevenzione e terapia delle malattie cardiovascolari su base aterosclerotica	Diabete: nuove prospettive terapeutiche
05/07/2018-06/07/2018	7° Clinical Update in Endocrinologia e Metabolismo	Le terapie biologiche Ipolipidemizzanti

Part X– Summary of Scientific Achievements

Product type	Number	Data Base	Start	End
Papers [international]	50	PubMed, Scopus, Web of Science	2001	Present

Total Impact factor*	413,318 (InCites Journal Impact Factor)
----------------------	---

Average Impact Factor per Product*	8,26 (InCites Journal Impact Factor)
Total Citations	2.130 (Web of Science)
Average Citations per Product	36,1 (Web of Science)
Hirsch (H) index	16 (Web of Science)

*Using impact factor of the year in which papers were published

Part XI– Selected Publications

List of the publications selected for the evaluation.

N	Publication (title, authors, reference data)	Impact Factor (InCites; 2017)	Impact Factor (InCites; publication year)
1	The ectonucleotide pyrophosphatase phosphodiesterase 1 (ENPP1) K121Q polymorphism modulates the beneficial effect of weight loss on fasting glucose in non-diabetic individuals. Maranghi M , Prudente S, D'Erasmo L, Morini E, Ciociola E, Coletta P, Verrienti A, Arciello S, Copetti M, Pellegrini F, Santini SA, Morano S, Filetti S, Trischitta V. <i>Nutr Metab Cardiovasc Dis.</i> 2013 Jun;23(6):505-10. doi: 10.1016/j.numecd.2011.11.003	3,875	3,875
2	Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids. Robciuc MR*, Maranghi M* , Lahikainen A, Rader D, Bensadoun A, Öörni K, Metso J, Minicocci I, Ciociola E, Ceci F, Montali A, Arca M, Ehnholm C, Jauhiainen M. <i>Arterioscler Thromb Vasc Biol.</i> 2013 Jul;33(7):1706-13. doi: 10.1161/ATVBAHA.113.301397	6,086	5,533
3	Acquired liver fat is a key determinant of serum lipid alterations in healthy monozygotic twin. Kaye SM, Maranghi M , Bogl LH, Kaprio J, Hakkarainen A, Lundbom J, Lundbom N, Rissanen A, Taskinen MR, Pietiläinen KH. <i>Obesity</i> (Silver Spring). 2013 Sep;21(9):1815-22. doi: 10.1002/oby.20228	4,042	4,389

4	Functional and morphological vascular changes in subjects with familial combined hypolipidemia: an exploratory analysis. Minicocci I, Cantisani V, Poggiogalle E, Favari E, Zimetti F, Montali A, Labbadia G, Pigna G, Pannozzo F, Zannella A, Ceci F, Ciociola E, Santini S, Maranghi M, Vestri A, Ricci P, Bernini F, Arca M. <i>Int J Cardiol</i>. 2013 Oct 9;168(4):4375-8. doi: 10.1016/j.ijcard.2013.05.053	4,034	6,175
5	The angiopoietin-like protein 3: a hepatokine with expanding role in metabolism Arca M, Minicocci I, Maranghi M. <i>Curr Opin Lipidol</i>. 2013 Aug;24(4):313-20. doi: 10.1097/MOL.0b013e3283630cf0	3,853	5,803
6	Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis. Minicocci I, Santini S, Cantisani V, Stitzel N, Kathiresan S, Arroyo JA, Martí G, Pisciotta L, Noto D, Cefalù AB, Maranghi M, Labbadia G, Pigna G, Pannozzo F, Ceci F, Ciociola E, Bertolini S, Calandra S, Tarugi P, Averna M, Arca M. <i>J Lipid Res</i>. 2013 Dec;54(12):3481-90. doi: 10.1194/jlr.P039875	4,505	4,703
7	The relation between glycemic control and HDL-C in type 2 diabetes: a preliminary step forward? Barbarossa G, Renzi A, D'Erasmo L, Gallo A, Grieco E, Rossetti M, Carnovale A, Santilli M, Mandosi E, Coletta P, Pergolini D, Morano S, Maranghi M. <i>Diabetes Res Clin Pract</i>. 2014 Apr;104(1):e26-8. doi: 10.1016/j.diabres.2013.12.061	2,548	2,538
8	Pharmacokinetics, pharmacodynamics and clinical efficacy of dapagliflozin for the treatment of type 2 diabetes. Maranghi M, Carnovale A, Durante C, Tarquini G, Tiseo G, Filetti S. <i>Expert Opin Drug Metab Toxicol</i>. 2015 Jan;11(1):125-37. doi: 10.1517/17425255.2015.986457	3,151	2,598
9	Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism. Minicocci I, Tikka A, Poggiogalle E, Metso J, Montali A,	4,505	4,81

	Ceci F, Labbadia G, Fontana M, Di Costanzo A, Maranghi M , Rosano A, Ehnholm C, Donini LM, Jauhiainen M, Arca M. <i>J Lipid Res.</i> 2016 Jun;57(6):1097-107. doi: 10.1194/jlr.P066183		
10	Risk stratification of neck lesions detected sonographically during the follow-up of differentiated thyroid cancer. Lamartina L, Grani G, Biffoni M, Giacomelli L, Costante G, Lupo S, Maranghi M , Plasmati K, Sponziello M, Trulli F, Verrienti A, Filetti S, Durante C. <i>J Clin Endocrinol Metab.</i> 2016 Aug;101(8):3036-44. doi: 10.1210/jc.2016-1440.	5,789	5,455
11	When Intensive Insulin Therapy (MDI) Fails in Patients With Type 2 Diabetes: Switching to GLP-1 Receptor Agonist Versus Insulin Pump. Cohen O, Filetti S, Castañeda J, Maranghi M , Glandt M. <i>Diabetes Care.</i> 2016 Aug;39 Suppl 2:S180-6. doi: 10.2337/dcS15-3029	13,397	11,857
12	Non-alcoholic fatty liver disease and subclinical atherosclerosis: A comparison of metabolically- versus genetically-driven excess fat hepatic storage. Di Costanzo A, D'Erasmo L, Polimeni L, Baratta F, Coletta P, Di Martino M, Loffredo L, Perri L, Ceci F, Montali A, Girelli G, De Masi B, Angeloni A, Catalano C, Maranghi M , Del Ben M, Angelico F, Arca M. <i>Atherosclerosis.</i> 2017 Feb;257:232-239. doi: 10.1016/j.atherosclerosis.2016.12.018	4,467	4,467
		60,252	62,203

Luogo e data

Roma, 17/10/2018

Firma

Maranghi M